• Inhalt
• Psoriasis
• Arthritis psoriatica - Psoriasisarthritis
• Spondylitis ankylosans
• Morbus Crohn
• Uveitis bei Kindern
• Atherosklerose-Entstehung

Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab.
 Bongartz T,  Harle P,  Friedrich S,  Karrer S,  Vogt T,  Seitz A,  Muller-Ladner U
Arthritis Rheum. 2005 Jan;52(1):280-2.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
 Mease PJ,  Gladman DD,  Ritchlin CT,  Ruderman EM,  Steinfeld SD,  Choy EH,  Sharp JT,  Ory PA,  Perdok RJ,  Weinberg MA;  Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Arthritis Rheum. 2005 Oct;52(10):3279-89.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
 Patel T,  Gordon KB.
Dermatol Ther. 2004;17(5):427-31. Review.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
D D Gladman, P J Mease, M A Cifaldi, R J Perdok, E Sasso and J Medich
Annals of the Rheumatic Diseases 2007;66:163-168
ard.bmj.com/cgi/content/abstract/66/2/163

Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
 Gladman DD,  Mease PJ,  Ritchlin CT,  Choy EH,  Sharp JT,  Ory PA,  Perdok RJ,  Sasso EH
University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada
Arthritis Rheum. 2007 Jan 30;56(2):476-488 [Epub ahead of print]
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab: in psoriatic arthritis
 Simpson D,  Scott LJ
Drugs. 2006;66(11):1487-96; discussion 1497-9.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
 Mease PJ,  Gladman DD,  Ritchlin CT,  Ruderman EM,  Steinfeld SD,  Choy EH,  Sharp JT,  Ory PA,  Perdok RJ,  Weinberg MA;  Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
Arthritis Rheum. 2005 Oct;52(10):3279-89.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial
 van der Heijde D,  Kivitz A,  Schiff MH,  Sieper J,  Dijkmans BA,  Braun J,  Dougados M,  Reveille JD,  Wong RL,  Kupper H,  Davis JC Jr; ATLAS Study Group
Arthritis Rheum. 2006 Jul;54(7):2136-46
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial
 Haibel H,  Rudwaleit M,  Brandt HC,  Grozdanovic Z,  Listing J,  Kupper H,  Braun J, Sieper J
Arthritis Rheum. 2006 Feb;54(2):678-81
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab in patients with Crohn's disease - safety and efficacy in an open-label single centre study.
 Seiderer J,  Brand S,  Dambacher J,  Pfennig S,  Jurgens M,  Goke B,  Ochsenkuhn T
Aliment Pharmacol Ther. 2007 Apr 1;25(7):787-96.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
 Peyrin-Biroulet L,  Laclotte C,  Bigard MA
Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
 Sandborn WJ,  Hanauer SB,  Rutgeerts PJ,  Fedorak RN,  Lukas M,  Macintosh DG,  Panaccione R,  Wolf D,  Kent JD,  Bittle B,  Li J,  Pollack PF.
Gut. 2007 Feb 13;
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
 Hinojosa J,  Gomollon F,  Garcia S,  Bastida G,  Cabriada JL,  Saro C,  Ceballos D,  Penate M,  Gassull MA;  Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis
Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
 Colombel JF,  Sandborn WJ,  Rutgeerts P,  Enns R,  Hanauer SB,  Panaccione R,  Schreiber S,  Byczkowski D,  Li J,  Kent JD,  Pollack PF
Gastroenterology. 2007 Jan;132(1):52-65.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
 Hanauer SB,  Sandborn WJ,  Rutgeerts P,  Fedorak RN,  Lukas M,  MacIntosh D,  Panaccione R,  Wolf D,  Pollack P
Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab therapy for childhood uveitis.
 Vazquez-Cobian LB,  Flynn T,  Lehman TJ.
J Pediatr. 2006 Oct;149(4):572-5.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab
 Gonzalez-Juanatey C,  Llorca J,  Sanchez-Andrade A,  Garcia-Porrua C,  Martin J,  Gonzalez-Gay MA.
Clin Exp Rheumatol. 2006 May-Jun;24(3):309-12
www.ncbi.nlm.nih.gov/entrez/query.fcgi